Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways

Ying Gao

Gary O. Rankin
Marshall University, rankin@marshall.edu

Youying Tu

Yi Charlie Chen

Follow this and additional works at: http://mds.marshall.edu/sm_bm

Part of the Chemical Actions and Uses Commons, Enzymes and Coenzymes Commons, and the Oncology Commons

Recommended Citation

This Article is brought to you for free and open access by the Faculty Research at Marshall Digital Scholar. It has been accepted for inclusion in Biochemistry and Microbiology by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu, martj@marshall.edu.
Abstract. Theaflavin-3, 3'-digallate (TF3) is a black tea polyphenol produced from polymerization and oxidation of the green tea polyphenols epicatechin gallate and (-)-epigallocatechin-3-gallate (EGCG) during fermentation of fresh tea leaves. TF3 has been reported to have anticancer properties. However, the effect of TF3 on tumor angiogenesis and the underlying mechanisms are not clear. In the present study, TF3 was verified to inhibit tumor angiogenesis. Compared with EGCG, TF3 was more potent. TF3 inhibited human ovarian carcinoma OVCAR-3 cell-induced angiogenesis in human umbilical vein endothelial cell model and in chick chorioallantoic membrane model. TF3 reduced tumor angiogenesis by downregulating HIF-1α and VEGF. One of the mechanisms was TF3 inactivated Akt/mTOR/p70S6K/4E-BP1 pathway and Akt/c-Myc pathway. Besides, TF3 suppressed the cleavage of Notch-1, subsequently decreased the expression of c-Myc, HIF-1α and VEGF, and finally the impaired cancer cells induced angiogenesis. Nevertheless, TF3 did not have any influence on the MAPK pathways. Taken together, these findings suggest that TF3 might serve as a potential anti-angiogenic agent for cancer treatment.

Introduction

Epithelial ovarian cancer is the most lethal gynecological cancer (1). Cytoreductive surgery with chemotherapy is the standard of care for ovarian cancer (2). However, 20-40% of patients do not respond to first-line chemotherapy (3). Furthermore, a large proportion of patients will have a relapse of the disease within 5 years (1), especially those in advanced stage. Unfortunately, recurrence is typically less responsive to current chemotherapeutic strategies (1).

Angiogenesis plays an important role in the growth and progression of solid tumors (4). Tumor angiogenesis is characterized by the formation of new irregular blood vessels from a preexisting vascular network (5). Tumor vasculature usually has poor blood flow and high vascular permeability, which may lead to decreased efficiency of cytotoxic chemotherapy and increased potential for metastasis (6). Angiogenesis can be regulated by many signaling molecules and growth factors, including vascular endothelial growth factor (VEGF). VEGF is a crucial factor in modulating multiple vascular steps. VEGF expression can be upregulated by hypoxia-inducible factor 1 (HIF-1). HIF-1 is a basic-loop helix PER-ARNT-SIM transcription factor consisting of two subunits, HIF-1α and HIF-1β. Overexpression of HIF-1α has been demonstrated in >70% of human cancers and metastases compared to adjacent normal tissue (7). Stabilization and upregulation of HIF-1α promotes the expression of VEGF by binding to HIF-responsive elements in promoters. Therefore, anti-angiogenic agents targeting HIF-1α and VEGF are highlighted for anticancer treatment.

Black tea is one of the most popular beverages worldwide. Basic procedures of making black tea include withering, rolling, fermentation, and drying. During the fermentation process, green tea polyphenols are polymerized and oxidized to form oligomeric flavonols, such as theaflavins, thearubigin and other oligomers (8). Thus black tea has low tea catechin content (9). Theaflavin-3, 3'-digallate account for 2-6% of the dry weight of solids in brewed black tea (9). Theaflavin-3, 3'-digallate (TF3)
(Fig. 1A) is one of the four main theaflavins in black tea, which is produced by the oxidative dimerization of epicatechin gallate (ECG) and (-)-epigallocatechin-3-gallate (EGCG). TF3 is a potent anticancer agent. It showed inhibitory effects on the growth of various human cancer cells (10). It induced apoptosis and cell cycle arrest in cancer cells by generating reactive oxygen species and/or modulating signaling pathways (8,11,12). Recently, theaflavins were observed to exhibit anti-angiogenic activities. TF3 inhibited tube formation in cocultured endothelial cells with fibroblasts (13). In human prostate cancer-bearing athymic nude mice, theaflavins significantly diminished the expression of VEGF in tumors (14). Nevertheless, the mechanisms remain unclear.

In the present study, the antitumor-induced angiogenic effect and mechanisms of TF3 were investigated. TF3 impaired human ovarian carcinoma OVCAR-3 cell-induced angiogenesis. Part of the underlying mechanisms was TF3 targeted Akt/mTOR/p70S6K pathway, Akt/c-Myc pathway and Notch-1/c-Myc pathway to regulating HIF-1α and VEGF expression in OVCAR-3 cells. Our study suggests that TF3 can be regarded as a candidate anti-angiogenic agent for the adjunctive therapy of cancer.

Materials and methods

**Cell cultures and reagents.** Human ovarian carcinoma cell line OVCAR-3, a kind gift from Dr Bing-Hua Jiang, Thomas Jefferson University, was cultured in RPMI-1640 medium (Sigma, St. Louis, MO, USA) incorporating 10% fetal bovine serum (FBS) (Invitrogen, Grand Island, NY, USA). Human umbilical vein endothelial cells (HUVECs), purchased from American Type Culture Collection (ATCC, Manassas, VA, USA), were maintained in F-12K medium (ATCC) supplemented with 10% FBS (Invitrogen) and Endothelial Cell Growth Kit-VEGF (ATCC). Cells were grown in a humidified incubator containing 5% CO₂ at 37°C.

**Reagents:** TF3 monomer (purity: 92.4%) was isolated and purified using previously established method (15). Wortmannin and N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT) were purchased from Sigma and Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against phospho-Akt from Sigma and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Antibodies against phospho-Akt (Ser473) (p-Akt), Akt, phospho-p70S6 kinase (Thr421/Ser424) (p-p70S6K), p70S6K, eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), HIF-1α, Notch-1, c-Jun N-terminal kinases (JNK), p38 and phosphor-Forhead Box O1 (Thr24) (p-FoxO1) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies against phosphor-mammalian target of rapamycin (p-mTOR) (Ser2448), mTOR were purchased from R&D Systems (Minneapolis, MN, USA). Antibodies against phosphor-4E-BP1 (Ser65/Thr70) (p-4E-BP1), c-Myc, phosphor-extracellular signal-regulated kinases 1/2 (Thr202/Tyr204) (p-ERK1/2), ERK1/2 and GAPDH were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz). Plasmids (myrAkt delta4-129, pcDNA3-Flag mTOR wt, pw2L) Neo Myr Flag RPS6K1B1, pET14b PHAS-I, HA-HIF1alpha-pcDNA3, 3XFlagNID1, pMXs-hc-MYC, ODD-Luciferase-pcDNA3, VEGF promoter, cMyc promoter (TBE1/2-wt), and pCBFRE-luc) were purchased from Addgene (Cambridge, MA, USA).

**Western blot analysis.** OVCAR-3 cells were treated for 24 h with various concentrations of TF3 in 60 mm dishes, and then lysed in 100 µl mammalian protein extraction reagent supplemented with Halt™ Protease and Phosphatase Inhibitor Single-Use Cocktail (Life Technologies, Grand Island, NY, USA). The concentration of protein was measured using a BCA Protein assay kit (Thermo, Waltham, MA, USA). Equal amounts of protein were prepared and separated by SDS-PAGE and transferred onto the nitrocellulose membranes with a Mini-Protein 3 system (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% non-fat milk in Tris-buffer saline containing 0.1% Tween-20 for 1 h at room temperature and incubated with indicated primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated secondary antibody for 2 h at 37°C. Detection was performed by SuperSignal West Dura Extended Duration Substrate (Life

**Cell viability assay.** OVCAR-3 cells were seeded into 96-well plates at a density of 2x10⁴ per well in medium with 10% FBS. After overnight growth, cells were treated with different concentrations of TF3 for 24 h. Cell viability was measured using CellTiter 96® Aqueous One Solution Cell Proliferation assay (Promega, Madison, WI, USA), according to the manufacturer's instructions. Cell viability was expressed as a percentage compared to control cells (vehicle treatment).

**HUVEC tube formation assay.** Growth factor-reduced Matrigel (50 µl) (BD Biosciences, San Jose, CA, USA) was added into each well of a 96-well plate and polymerized for 30 min at 37°C. HUVECs (1.5x10⁵/well) in 100 µl conditioned medium (90 µl F12-K medium+10 µl cell culture supernatant of vehicle or TF3-treated OVCAR-3 cells) were seeded into each growth factor-reduced Matrigel-coated well, incubated at 37°C in 5% CO₂ for 6 h, and photographed under a microscope. Tube length was quantified using the NIH ImageJ software (NIH, Bethesda, MD, USA). Tube length was expressed as a percentage compared to the control group.

**Chick chorioallantoic membrane (CAM) assay.** Specific pathogen-free fertile chicken eggs (Charles River Laboratories, North Franklin, CT, USA) were incubated at 37.5°C and slowly turned by an automatic egg turner (G.Q.F. Manufacturing Co., Savannah, GA, USA). On the 8th day of development of fertilized chicken eggs, a 1-cm diameter window was opened in the shell of each egg to expose the CAM. On the 9th day, 10⁶ OVCAR-3 cells in 20 µl FBS-free RPMI-1640 medium were mixed with 80 µl Matrigel (BD Biosciences), supplemented with TF3 at a final concentration of 25 µmol/l (µM) or equivalent vehicle, and implanted onto the CAM. After incubating for another 5 days, tumor implants and blood vessels were photographed and counted for branching blood vessels. Blood vessel density was normalized to the control group.

**Enzyme linked immunosorbent assays.** OVCAR-3 cells were seeded into 96-well plates at a density of 2x10⁴ per well, incubated overnight and treated with different concentrations of TF3 for 24 h. Cell culture supernatants were collected. The concentration of human VEGF protein was determined by a human VEGF Duo-set ELISA kit (R&D) according to the manufacturer's instructions.

**Materials and methods**

**Chick chorioallantoic membrane (CAM) assay.** Specific pathogen-free fertile chicken eggs (Charles River Laboratories, North Franklin, CT, USA) were incubated at 37.5°C and slowly turned by an automatic egg turner (G.Q.F. Manufacturing Co., Savannah, GA, USA). On the 8th day of development of fertilized chicken eggs, a 1-cm diameter window was opened in the shell of each egg to expose the CAM. On the 9th day, 10⁶ OVCAR-3 cells in 20 µl FBS-free RPMI-1640 medium were mixed with 80 µl Matrigel (BD Biosciences), supplemented with TF3 at a final concentration of 25 µmol/l (µM) or equivalent vehicle, and implanted onto the CAM. After incubating for another 5 days, tumor implants and blood vessels were photographed and counted for branching blood vessels. Blood vessel density was normalized to the control group.

**Enzyme linked immunosorbent assays.** OVCAR-3 cells were seeded into 96-well plates at a density of 2x10⁴ per well, incubated overnight and treated with different concentrations of TF3 for 24 h. Cell culture supernatants were collected. The concentration of human VEGF protein was determined by a human VEGF Duo-set ELISA kit (R&D) according to the manufacturer's instructions.

**Western blot analysis.** OVCAR-3 cells were treated for 24 h with various concentrations of TF3 in 60 mm dishes, and then lysed in 100 µl mammalian protein extraction reagent supplemented with Halt™ Protease and Phosphatase Inhibitor Single-Use Cocktail (Life Technologies, Grand Island, NY, USA). The concentration of protein was measured using a BCA Protein assay kit (Thermo, Waltham, MA, USA). Equal amounts of protein were prepared and separated by SDS-PAGE and transferred onto the nitrocellulose membranes with a Mini-Protein 3 system (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% non-fat milk in Tris-buffer saline containing 0.1% Tween-20 for 1 h at room temperature and incubated with indicated primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated secondary antibody for 2 h at 37°C. Detection was performed by SuperSignal West Dura Extended Duration Substrate (Life
Technologies) and ChemiDoc™ MP System (Bio-Rad). Protein bands were quantified with the NIH ImageJ software (NIH), normalized by corresponding GAPDH for analysis.

Figure 1. Theaflavin-3, 3’-digallate (TF3) inhibits OVCAR-3 cell-induced angiogenesis by targeting HIF-1α and VEGF. (A) Molecular structure of TF3. (B) Viability of OVCAR-3 cells was decreased after TF3 treatment for 24 h. (C) OVCAR-3 cells-induced HUVEC tube formation was inhibited by TF3 treatment. (D) OVCAR-3 cell-induced blood vessel development in the CAM model was reduced by TF3 treatment. (E) The protein level of VEGF in TF3-treated OVCAR-3 cell culture supernatant was reduced. (F) TF3 diminished the transcriptional activity of VEGF promoter, and, overexpression of HIF-1α reversed it. The data are presented as the mean ± standard error of mean. *P<0.05 compared with control or between specific groups.

Transient transfection and luciferase reporter assay. OVCAR-3 cells were seeded in 96-well plates at a density of 2x10^4 per well and transfected with plasmids (including
a targeted gene plasmid, a corresponding luciferase reporter plasmid and β-galactosidase control vector) using jetPrime™ DNA and siRNA Transfection reagent (VWR International, West Chester, PA, USA). Four hours later, medium was replaced by FBS-free RPMI-1640 medium containing TF3 or equivalent vehicle. Cells were incubated for another 24 h.

Luciferase assays and β-galactosidase assay were performed using One-Glo™ luciferase assay system and β-galactosidase enzyme assay system (Promega), respectively. Luciferase activity was expressed relative to β-galactosidase activity.

Statistical analysis. The data are expressed as mean ± standard error of mean (SEM) from at least three independent experiments. The results were analyzed with SPSS Version 18.0 for Windows (SPSS, Chicago, IL, USA) using one-way analysis of variance (ANOVA) and post hoc test (2-sided Dunnett’s test) to test both overall differences and specific differences between each treatment and control. P-values <0.05 were considered statistically significant.

Results

TF3 reduces tumor-induced angiogenesis in vitro and in vivo by downregulating VEGF and HIF-1α. To evaluate the cytotoxicity of TF3 on OVCAR-3 cells, CellTiter 96® Aqueous One Solution Cell Proliferation assay was performed (Fig. 1B). TF3 treatment for 24 h dose-dependently inhibited the viability of OVCAR-3 cells, ranging from 100 to 48.3%. The anti-proliferative activity of TF3 is weak at low concentrations. The viability of OVCAR-3 cells was >70% when treated with concentrations of 15 µM and below of TF3.

Black tea extracts, which contains theaflavins, has been reported to inhibit tumor angiogenesis. To assess whether TF3 repressed angiogenesis induced by OVCAR-3 cells, HUVEC tube formation assay was carried out. HUVECs were cultured in F12-K medium supplemented with cell culture supernatant of vehicle or TF3-treated OVCAR-3 cells. Mature, interconnected capillary-like networks were observed in the control group. However, the tube-like structures found in TF3-treated groups were less organized and leaky. Tube length was determined to quantify tube formation. The data showed TF3 interrupted OVCAR-3 cell-induced HUVEC tube formation in a dose-dependent manner (Fig. 1C).

To examine the anti-angiogenic potential of TF3 in vivo, CAM assay was conducted. Highly vascularized structure was found in the control group. TF3 treatment markedly reduced blood vessel density. These results confirmed that TF3 inhibited cancer cells induced angiogenesis in vivo (Fig. 1D).

VEGF is an important growth factor involved in tumor vascular development and maintenance. We examined the effect of TF3 on VEGF secretion using a VEGF ELISA kit. The protein level of VEGF in TF3-treated OVCAR-3 cell culture supernatant was much lower compared with that in the control group. TF3 had an excellent activity on diminishing the secretion of VEGF (Fig. 1E), indicating TF3 inhibited tumor angiogenesis by targeting VEGF.

HIF-1α has a direct regulatory impact on the expression of VEGF. Western blot analysis revealed that TF3 significantly
decreased the protein level of HIF-1α in OVCAR-3 cells (Fig. 2). The data of luciferase reporter assay implied TF3 strongly eliminated the transcriptional activity of VEGF promoter. However, this inhibitory effect was abrogated by overexpression of HIF-1α (Fig. 1F). It hinted TF3 downregulated VEGF by repressing HIF-1α expression in OVCAR-3 cells.

TF3 inhibits HIF-1α and VEGF via Akt/mTOR/p70S6K/4E-BP1 pathway. Previous studies demonstrated that PI3K/Akt signaling was required for VEGF expression through HIF-1 in response to growth factor stimulation and oncogene activation (16). mTOR/p70S6K/RPS6/4E-BP1 signaling pathway also played an important role in suppressing HIF-1α and VEGF expression (17). To explore whether TF3 decreased HIF-1α and VEGF expression via Akt pathway, the protein levels of PTEN, p-Akt, Akt, p-mTOR, mTOR, p-p70S6K, p70S6K, p-4E-BP1 and 4E-BP1 were detected by western blot analysis. As shown in Fig. 2, TF3 significantly lowered the protein levels of p-Akt, p-mTOR, p-p70S6K and p-4E-BP1. Whereas, the expression of PTEN, a negative regulator of the Akt pathway, was not affected by TF3 treatment. The result indicated that TF3 inactivated Akt pathway through inhibiting the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1 in OVCAR-3 cells.

When treated with TF3 and wortmannin, a selective Akt pathway inhibitor, an additive inhibitory effect on Akt pathway was observed in OVCAR-3 cells. The protein levels of p-Akt, p-mTOR, p-p70S6K, p70S6K, p-4E-BP1 and 4E-BP1 were detected by western blot analysis. As shown in Fig. 2, TF3 significantly lowered the protein levels of p-Akt, p-mTOR, p-p70S6K and p-4E-BP1. Whereas, the expression of PTEN, a negative regulator of the Akt pathway, was not affected by TF3 treatment. The result indicated that TF3 inactivated Akt pathway through inhibiting the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1 in OVCAR-3 cells.

When treated with TF3 and wortmannin, a selective Akt pathway inhibitor, an additive inhibitory effect on Akt pathway was observed in OVCAR-3 cells. The protein levels of p-Akt, p-mTOR, p-p70S6K, p70S6K, p-4E-BP1 and 4E-BP1 were detected by western blot analysis. As shown in Fig. 2, TF3 significantly lowered the protein levels of p-Akt, p-mTOR, p-p70S6K and p-4E-BP1. Whereas, the expression of PTEN, a negative regulator of the Akt pathway, was not affected by TF3 treatment. The result indicated that TF3 inactivated Akt pathway through inhibiting the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1 in OVCAR-3 cells.

When treated with TF3 and wortmannin, a selective Akt pathway inhibitor, an additive inhibitory effect on Akt pathway was observed in OVCAR-3 cells. The protein levels of p-Akt, p-mTOR, p-p70S6K, p70S6K, p-4E-BP1 and 4E-BP1 were detected by western blot analysis. As shown in Fig. 2, TF3 significantly lowered the protein levels of p-Akt, p-mTOR, p-p70S6K and p-4E-BP1. Whereas, the expression of PTEN, a negative regulator of the Akt pathway, was not affected by TF3 treatment. The result indicated that TF3 inactivated Akt pathway through inhibiting the phosphorylation of Akt, mTOR, p70S6K and 4E-BP1 in OVCAR-3 cells.
Figure 3. Continued. Overexpression of Akt, mTOR, p70S6K or 4E-BP1 attenuated TF3-induced inhibition of transcriptional activity of VEGF promoter (E) and HIF-1α promoter (F). (G) Overexpression of active Akt reversed the 15 µM TF3-induced reduction of VEGF secretion. The data are presented as the mean ± standard error of mean. *P<0.05 compared with control or between specific groups.
Figure 4. Notch-1/c-Myc pathway is related to TF3-induced inhibition of HIF-1α and VEGF. (A) Western blot analysis showed that 10 µM TF3, 75 µM DAPT and 10 µM TF3+75 µM DAPT decreased the expression of NICD, c-Myc and HIF-1α. The dose of 10 µM TF3+75 µM DAPT exhibited the strongest effect. GAPDH served as the loading control. (B) Luciferase reporter assay and (C) VEGF ELISA showed 10 µM TF3, 75 µM DAPT and 10 µM TF3+75 µM DAPT suppressed the transcriptional activity of VEGF promoter and VEGF secretion, respectively. (D) Overexpression of NICD attenuated 15 µM TF3-induced decrease of NICD, c-Myc and HIF-1α. (E) Overexpression of NICD or c-Myc attenuated TF3-induced inhibition of transcriptional activity of VEGF promoter and HIF-1α promoter. (F) Overexpression of NICD or active Akt attenuated TF3-induced inhibition of transcriptional activity of c-Myc promoter. (G) Overexpression of NICD reversed the 15 µM TF3-induced reduction of VEGF secretion. The data are presented as the mean ± standard error of mean. *P<0.05 compared with control or between specific groups.
promoter was lower than that in TF3 or wortmannin alone treated cells (Fig. 3B). On the contrary, transfected OCVAR-3 cells with a plasmid expressing constitutively active Akt made the cells less responsive to TF3 treatment. TF3-mediated decrease in the protein levels of p-Akt, p-mTOR, p-p70S6K, p-4E-BP1, HIF-1α and VEGF was partially attenuated in Akt-overexpressing OVCAR-3 cells (Fig. 3D and G). Besides, transfected cells with plasmid expressing Akt, mTOR, p70S6K or 4E-BP1 reversed TF3-induced transcription inhibition of VEGF promoter and HIF-1α promoter (Fig. 3E and F). These data provided evidence that TF3 reduced HIF-1α and VEGF via Akt/mTOR/p70S6K/4E-BP1 pathway in OVCAR-3 cells.

TF3 suppresses HIF-1α and VEGF via Akt/c-myc and Notch-1/c-myc pathway. c-Myc is a major human oncogene which exerts many biological functions. It has been elucidated that c-Myc enhances cancer cell-mediated angiogenesis through the regulation of HIF-1α (18). c-Myc expression can be regulated in an Akt-dependent manner at the level of transcription (19). c-Myc expression also can be affected by Notch-1. Notch-1 upregulates c-Myc transcription by directly binding to its promoter (20). To investigate whether Akt/c-Myc and Notch-1/c-Myc participated in tumor angiogenesis and the influence of TF3 on these pathways, western blot analysis and luciferase reporter assay were carried out. According to the results, TF3 significantly suppressed the expression of c-Myc, HIF-1α and VEGF, the cleavage of Notch-1, and the phosphorylation of Akt (Figs. 1E and 2). TF3 and wortmannin co-treatment enhanced the effect of TF3 on decreasing the protein levels of c-Myc, HIF-1α and VEGF (Fig. 3A and C), while overexpression of active Akt rescued it (Fig. 3D and G). Similarly, exposure to the combination of TF3 and DAPT, a Notch inhibitor, caused a stronger repression of c-Myc and HIF-1α than DAPT or TF3 alone (Fig. 4A). Whereas, overexpression of Notch-1 intracellular domain (NICD) had an adverse effect on the TF3-triggered inhibition of c-Myc, HIF-1α and VEGF expression (Fig. 4D and G). Luciferase reporter assay confirmed that wortmannin, DAPT and TF3 declined the transcriptional activity of VEGF promoter (Figs. 3B and 4B). On the contrary, overexpression of active Akt or NICD abrogated TF3-induced transcription inhibition of c-Myc promoter, HIF-1α promoter and VEGF promoter (Figs. 3E and F, and 4E and F). Transfected cells with plasmid expressing c-Myc eliminated TF3-induced transcription inhibition of HIF-1α and VEGF (Fig. 4E). Taken together, Akt/c-Myc/HIF-1α/VEGF pathway and Notch-1/c-Myc/HIF-1α/VEGF pathway are involved in the antitumor angiogenic mechanisms of TF3.

TF3 does not affect HIF-1α and VEGF via the MAPK pathways. MAPK pathways play essential roles in cell proliferation and differentiation. Activation of MAPK signaling pathways has been reported to participate in tumorigenesis, metastasis, and angiogenesis of multiple human malignancies (21). To investigate whether TF3 had an influence on MAPK pathways, western blot assay was carried out. In this study, TF3 showed no sign of affecting the protein levels of p-ERK1/2, ERK1/2, JNK, p38 and p-FoxO1 (Fig. 5), suggesting MAPK pathways were not relevant to the antitumor angiogenic activity of TF3.
Discussion

Ovarian cancer is one of the most common cancers in women. Due to the fact that current chemotherapies do not work on a proportion of patients and may cause severe side effect, it is critical to identify alternative strategies. Some nutrients were found to have anticancer activities with little side effect. A previous study presented that black tea consumption was associated with a linear decline in ovarian cancer risk (22). TF3 is produced in black tea manufacturing process. It has multiple biological activities, including the anti-oxidant, anti-bacterial, anti-obese, and anticancer effects. TF3 inhibits proliferation and/or induce apoptosis of various cancer cells (11,12). In this study, we tested the cytotoxicity of TF3 on OVCAR-3 cells and found TF3 inhibited cell proliferation, especially at high concentrations. This is consistent with the former research that theaflavins exhibited anti-proliferative and apoptotic activity in human teratocarcinoma of ovarian origin (23). Although previous studies and the current study proved TF3 exerted an anti-proliferative effect of cancer cells, the working concentrations were much higher than the attainable concentrations of TF3 in plasma and tissues (24).

Previous studies showed that some food-derived natural compounds elicited growth inhibitory activity at higher concentrations while anti-angiogenic activity at relatively lower concentrations (25,26). Tumor angiogenesis is related with poor prognosis in ovarian carcinoma (27). Cancer cells can secrete pro-angiogenic factors, including VEGF and basic fibroblast growth factor, to stimulate normal endothelial cell growth through paracrine mechanisms (28). VEGF regulates the key steps of angiogenic process, particularly endothelial cell proliferation, survival, permeability, and migration (29). TF3 has been demonstrated to inhibit gene expression of VEGF in A549 lung cancer cells (30). However, the impact of TF3 on ovarian cancer-induced angiogenesis has not been reported yet. To explore whether TF3 hampered tumor induced angiogenesis, we tested the anti-angiogenic activity of TF3 in the HUVEC model and CAM model, and the VEGF protein content in the cell culture supernatant of TF3-treated OVCAR-3 cells. In this study, TF3 was verified to block OVCAR-3 cell-triggered HUVEC tube formation and blood vessel development in the CAM model. TF3 started to inhibit HUVEC tube formation at 5 µM. About half of OVCAR-3 cell-induced HUVEC tube formation was blocked after 15 µM TF3 treatment. The result of VEGF ELISA was in accordance with that of tube formation assay. TF3 strongly reduced the VEGF secretion of OVCAR-3 cells. Treatment with 5 µM TF3 caused an ~50% decline of VEGF secretion. The data implied that TF3 might exert its antitumor angiogenic function by downregulating VEGF. It also provided evidence supporting a multifunction of TF3 on OVCAR-3 cells between different concentrations. In the present study, we also measured the effect of EGCG, a precursor of TF3, on VEGF secretion of OVCAR-3 cells. EGCG was regarded as one of the most potent bioactives in green tea and has been proven to inhibit tumor angiogenesis (31). Compared with EGCG, the working concentration of TF3 was much lower (Fig. 5D). One of the possible reasons might be that TF3 was more stable than EGCG in aqueous system (pH 7.4) (32). Structural differences might also be responsible for this (Figs. 1A and 5B). The activity of tea polyphenols is related with the number and position of hydroxyl groups in molecules (33). TF3 is produced by the oxidative dimerization of ECG and EGCG. Therefore, TF3 contains more hydroxyl groups than ECG or EGCG alone.

HIF-1α is a subunit of the heterodimeric transcription factor HIF-1, which regulates the transcription of >60 genes, including VEGF. Dysregulation and overexpression of HIF-1α are heavily implicated in cancer biology, specifically in areas of vascularization and angiogenesis. Constitutively elevated levels of HIF-1α protein were detected under normal conditions in OVCAR-3 cells (16). We observed TF3 remarkably decreased the expression of HIF-1α in OVCAR-3 cells. Luciferase reporter assay suggested TF3 inhibited VEGF by suppressing HIF-1α. EGCG has been reported to suppress breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and expression of VEGF (34). Similar functions of EGCG were also found in human cervical carcinoma and hepatoma cells (35). It suggested that HIF-1α/VEGF might be key therapeutic targets for tea polyphenols.

Multiple signaling pathways are involved in the regulation of HIF-1α/VEGF. One of them is the Akt signaling pathway. Akt signaling pathway has been considered to participate in angiogenesis in the neoplastic and non-neoplastic process (36). Growth factors, cytokines, and other signaling molecules stimulate HIF-1 protein synthesis via activation of Akt pathway (16). The activation of Akt pathway starts from the phosphorylation of Akt. Then, mTOR can be phosphorylated and activated by Akt. Subsequently, activated mTOR regulates the phosphorylation and activation of p70S6K and 4E-BP1, two known downstream targets of mTOR (37). Active p70S6K and 4E-BP1 enhance the translation of mRNAs that bear a 5′ terminal oligopyrimidine tract, which encodes proteins related with the translational apparatus like ribosomal proteins, elongation factors and the poly A-binding protein (38). In the present study, we proved TF3 markedly decreased the phosphorylation of Akt, mTOR, p70S6K, and 4E-BP1, reduced the expression of HIF-1α and VEGF. This effect was potentiated by the PI3K/Akt inhibitor wortmannin.
and impaired by overexpression of active Akt. This is the first report that Akt/mTOR/p70S6K/4E-BP1/HIF-1α/VEGF pathway was involved in the anti-angiogenic effect of TF3. Recently, some natural compounds have been proven to inhibit HIF-1α and VEGF expression by targeting Akt signaling pathway. Quercetin, a flavonoid found in many fruits and vegetables, inhibited angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated Akt/mTOR/p70S6K signaling pathways (39). Silibinin, a natural flavonoid extracted from the milk thistle seeds, suppressed HIF-1α and mTOR/p70S6K/4E-BP1 signaling pathway in human cervical and hepatoma cancer cells (17). Tanshinone IIA, a derivative of phenanthrene-quinoine from the dried root of *Salvia miltiorrhiza*, regulated breast cancer growth and tumor angiogenesis via mTOR/p70S6K/RPS6/4E-BP1-mediated repression of HIF-1α and VEGF expression (37). Our study was in agreement with the previous studies and suggested that Akt/mTOR/p70S6K/4E-BP1/HIF-1α/VEGF pathway was an important target for plant-derived nutrients to inhibit tumor angiogenesis.

c-Myc is a transcription factor essential for vasculogenesis and angiogenesis during development and tumor progression (40). Targeting c-Myc/HIF-1α pathway inhibits cancer growth and angiogenesis (41).

Akt pathway has an influence on c-Myc (19). LY294002, a PI3K/Akt inhibitor, reduced c-Myc expression and regulated the degradation of c-Myc via affecting the phosphorylation status of Thr58 (19). In this study, western blot analysis revealed that c-Myc expression and phosphorylation of Akt was greatly inhibited by TF3. Hence, we hypothesized that Akt/c-Myc/HIF-1α pathway might be related to the anti-tumor angiogenic effect of TF3. To confirm this hypothesis, western blot and luciferase reporter assay were performed. Both TF3 and wortmannin inhibited the activation of Akt, expression of c-Myc, HIF-1α and VEGF. TF3 and wortmannin combination led to a more effective suppression. Conversely, transfected cells with plasmid expressing active Akt enhanced TF3-resistance of OVCAR-3 cells. These results indicated that TF3 inhibited HIF-1α and VEGF via Akt/c-Myc pathway. Akt/c-Myc pathway has been discovered to have an impact on cellular metabolism, cell proliferation and the cell cycle. Akt or c-Myc alone has been proven to regulate angiogenesis via HIF-1α/VEGF pathway. In this study, Akt and c-Myc was demonstrated to be relevant in stimulating tumor angiogenesis. Akt regulated the pro-angiogenic effect of c-Myc through modulating the expression of c-Myc. Thus, we discovered a novel target pathway responsible for the anti-angiogenic activity of TF3 in OVCAR-3 cells.

Notch-1 is important upstream of c-Myc. It modulates the expression of c-Myc by directly binding to its promoter. Notch-1 is a type I transmembrane receptor. When binding to its ligands, metalloproteinase-mediated and γ-secretase-mediated cleavage is induced. Subsequently, NICD is released from plasma membrane, translocated into the nucleus, and binds CBP-1/Suppressor of Hairless/Lag-1, mastermind-like-1, and p300/CPB, to form a transcriptional coactivator (42). Notch-1 is a regulator of tumor angiogenesis (43). Previous studies showed overexpression of Notch-1 promoted cell growth and tumor angiogenesis in myeloma (44). Whereas, Notch-1 antibody presents an adverse effect on tumor growth and angiogenesis (45). β-elemene, a sesquiterpene found in a variety of plants, has been demonstrated to attenuate angiogenesis capacity of CD44+ gastric cancer stem-like cells by interfering with the expression of Notch-1 (46). Notch-1 signaling is active in ovarian cancer (47). In the present study, we observed TF3 inhibited the cleavage of Notch-1. To verify whether there was a link between Notch-1/c-Myc pathway and HIF-1α/VEGF pathway, DAPT, a γ-secretase inhibitor was used. According to the results, DAPT lowered the expression of NICD, c-Myc, HIF-1α and VEGF. It hinted that HIF-1α and VEGF were regulated by Notch-1/c-Myc pathway in OVCAR-3 cells. Further experiments revealed that TF3 promoted the repressive effect of DAPT on Notch-1/c-Myc pathway. On the contrary, overexpression of NICD hampered TF3-triggered inhibition of these proteins. Based on the above results, we concluded that TF3 downregulated HIF-1α and VEGF partially by suppressing Notch-1/c-Myc pathway. The protein level of NICD in TF3 and/or DAPT treated cells was control group>TF3 group>DAPT group>TF3+DAPT group, while the protein levels of c-Myc and HIF-1α were control group>DAPT group>TF3 group>TF3+DAPT group. This inconsistence could be explained by TF3 suppressing c-Myc/ HIF-1α pathway not only via Notch-1, but also other targets (for example, Akt pathway). Besides, the combination of TF3 and DAPT failed to cause an additive effect on decreasing VEGF secretion, implying Notch-1/c-Myc pathway might only play a subordinate role in the anti-angiogenic function of TF3.

MAPK pathways regulate many cellular activities, including angiogenesis. MAPKs are activated by the dual phosphorylation of neighboring threonine and tyrosine residues in response to various extracellular stimuli (48). ERK, JNK and p38 are three major groups of MAPKs. ERKs are often activated by growth signals, while JNK and p38 are often initiated by stress-responsive signaling (48). FoxO1 is a forkhead transcription factor which specifically regulates a nonredundant, but overlapping set of angiogenesis- and vascular remodeling-related genes (49). FoxO1 contains 15 consensus phosphorylation sites for the MAPK family. It has been demonstrated that ERK and p38 directly regulated the transcriptional activity of FoxO1 via phosphorylation (50). Similarly, JNK-dependent phosphorylation of FoxO proteins results in nuclear accumulation and enhanced transcriptional activity (51). In the former studies, EGCG inhibited tumor angiogenesis through inactivating ERK1/2 in human colon carcinoma cells (52) and human pancreatic tumors (53). EGCG increased the activity of p38, but not ERK 1/2 in OVCAR-3 cells (54). In HUVECs, inhibition of PI3K/AKT and MEK/ ERK pathways enhanced the anti-angiogenic effects of EGCG through activation of FoxO transcription factors (48). However, we did not observe any effect of TF3 on ERK1/2, JNK or p38 in this case. This result implicated that although TF3 and EGCG shared some anti-angiogenic targets, they had their specific targets. This might be related to their molecular structures. TF3 possesses a benzotropolone skeleton that is formed from co-oxidation of EGCG and ECG, one with a vic-trihydroxy moiety and the other with an ortho-dihydroxy structure (9). The benzotropolone moiety has been proven to be important in the antioxidant activity (55), anti-inflammatory activity (56), anti-peptide transport activity and activating AMP-activated protein kinase (57). Thus, we speculated that
benzotropolone moiety might also be vital for its anticancer activity. Quantitative structure-activity relationship analysis should be carried out to investigate this assumption.

In conclusion, this study presented that TF3 had the ability to inhibit ovarian cancer cell-induced angiogenesis in vitro and in vivo. TF3 exerted this effect through suppression of HIF-1α and VEGF. One of the mechanisms is that TF3 inhibited Akt/mTOR/p70S6K/4E-BP1 pathway. Other mechanisms included TF3-mediated inactivation of Akt/c-Myc and Notch-1/c-Myc pathways. MAPK pathways were not involved. This study provides novel perspectives and potential targets for the anticancer activity of TF3 (Fig. 6). Further studies in animal models and human trials are needed to evaluate the antitumor angiogenic activity of TF3.

Acknowledgements

The authors acknowledge financial support from the West Virginia Higher Education Policy Commission/Division of Science Research. This study was also supported by NIH grants P20RR016477 from the National Center for Research Resources and P20GM103434 from the National Institute for General Medical Sciences (NIGMS) awarded to the West Virginia IDEA Network of Biomedical Research Excellence.

References

10. Tu YY, Tang AB and Watanabe N: The theaflavin monomers TF3 exerted this effect through suppression of HIF-1α and VEGF. One of the mechanisms is that TF3 inhibited Akt/mTOR/p70S6K/4E-BP1 pathway. Other mechanisms included TF3-mediated inactivation of Akt/c-Myc and Notch-1/c-Myc pathways. MAPK pathways were not involved. This study provides novel perspectives and potential targets for the anticancer activity of TF3 (Fig. 6). Further studies in animal models and human trials are needed to evaluate the antitumor angiogenic activity of TF3.


291


